Andrew Combs Acquires 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider Andrew Combs acquired 60,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $1.37 per share, for a total transaction of $82,200.00. Following the completion of the transaction, the insider now directly owns 377,623 shares of the company’s stock, valued at approximately $517,343.51. This represents a 18.89 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Andrew Combs also recently made the following trade(s):

• On Friday, December 20th, Andrew Combs bought 3,075 shares of Prelude Therapeutics stock. The shares were acquired at an average cost of $1.15 per share, for a total transaction of $3,536.25.

Prelude Therapeutics Trading Up 17.6 %

NASDAQ:PRLD opened at $1.40 on Friday. The business’s 50-day moving average is $1.16 and its 200 day moving average is $3.10. Prelude Therapeutics Incorporated has a 12 month low of $0.80 and a 12 month high of $6.80. The company has a market capitalization of $77.05 million, a P/E ratio of -0.79 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The firm had revenue of $3.00 million for the quarter. On average, research analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PRLD shares. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Hedge Funds Weigh In On Prelude Therapeutics

Several institutional investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after buying an additional 12,564 shares during the last quarter. Geode Capital Management LLC increased its stake in Prelude Therapeutics by 8.2% during the third quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after acquiring an additional 29,765 shares during the last quarter. XTX Topco Ltd purchased a new stake in Prelude Therapeutics during the third quarter valued at approximately $100,000. State Street Corp lifted its stake in shares of Prelude Therapeutics by 35.1% in the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock valued at $592,000 after purchasing an additional 74,300 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Prelude Therapeutics by 885.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after purchasing an additional 157,218 shares during the period. Institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.